The Peptide Advantage Retatrutide Dosing Protocol: Fact Check

The Peptide Advantage Retatrutide Dosing Protocol: Fact Check

Vinnie, host of The Peptide Advantage, published a "beginner protocol" for retatrutide recommending 333 micrograms injected three times per week, a 10-12 week cycle, and stacking with a branded probiotic and metformin supplement. He also asks viewers to drop their email addresses in the comments for a full dosing protocol PDF.

This page fact-checks every claim in the video against published clinical trial data from the Phase 2 NEJM paper and Phase 3 TRIUMPH program.

The 3x/Week Dosing Protocol

Vinnie recommends starting with 333 micrograms of retatrutide injected three times per week on non-consecutive days (Monday/Wednesday/Friday or Tuesday/Thursday/Saturday). This totals approximately 1 mg per week split across three injections.

ClaimPublished DataVerdict
Dose retatrutide 3 times per weekEvery published clinical trial — Phase 1, Phase 2 (NEJM, 2023), and Phase 3 TRIUMPH program — used once-weekly subcutaneous injection. Retatrutide has a mean half-life of approximately 6 days, which is why it was designed as a once-weekly drug.Contradicted by all trial data
333 mcg per injection (about 1 mg/week total)The lowest dose tested in the Phase 2 trial was 1 mg once weekly. At that dose, participants lost 8.7% body weight at 48 weeks — the least effective arm. The Phase 3 TRIUMPH-4 trial tested 9 mg and 12 mg once weekly.Untested protocol
Non-consecutive days to minimize side effectsNo published research has studied split-dose retatrutide administration. Splitting a once-weekly drug into 3 sub-doses may produce subtherapeutic peak concentrations and unpredictable pharmacokinetics.No evidence

This is the most significant problem with the video. Retatrutide was designed, manufactured, and tested exclusively as a once-weekly injection. The 3x/week protocol is entirely fabricated — it does not appear in any clinical trial, case report, or pharmacokinetic study. The drug\u0027s ~6-day half-life is specifically why Eli Lilly developed it for weekly administration.

For context, even the lowest dose tested in trials (1 mg once weekly) produced modest results. Splitting that same weekly total into three sub-therapeutic micro-injections has no scientific basis. For how retatrutide is actually dosed in clinical trials, see Retatrutide Dosage.

Reconstitution Math

Vinnie walks through reconstituting a 10 mg research peptide vial with 3 ml of bacteriostatic water, then drawing 10 IU (0.1 ml) per dose to get 333 mcg.

ClaimPublished DataVerdict
10 mg vial + 3 ml BAC water = 3.33 mg/mlThe arithmetic is correct: 10,000 mcg / 3 ml = 3,333 mcg/ml. Drawing 0.1 ml (10 IU on an insulin syringe) delivers 333 mcg.Math is correct
The vial will last 10-11 weeksAt 3 doses per week of 0.1 ml each (0.3 ml/week), 3 ml would last exactly 10 weeks. The math checks out for his protocol.Math is correct

The reconstitution arithmetic is accurate. However, this is a recipe for preparing grey market research peptides — not FDA-approved medication. Retatrutide is an investigational drug that has not been approved by any regulatory agency. The video is effectively teaching viewers how to self-administer an unapproved drug using an unvalidated dosing protocol. For more on the risks of grey market peptides, see Grey Market Retatrutide.

The 10-12 Week Cycle

Vinnie recommends sticking with the protocol for 10-12 weeks before reassessing weight, appetite, labs, and overall well-being.

ClaimPublished DataVerdict
10-12 week beginner cycleThe Phase 2 trial ran for 48 weeks. Phase 3 TRIUMPH-4 ran for 68 weeks. In clinical trials, the dose escalation period alone takes 12 weeks to reach the target dose. By 10-12 weeks, participants were only just reaching their maintenance dose.Contradicted by trial design
Reassess and decide whether to increase or take a maintenance breakGLP-1 receptor agonists are not designed for short cycles. Weight regain after discontinuation is well-documented across the class (semaglutide, tirzepatide). There is no published data supporting a 10-12 week course of retatrutide for sustained results.Misleading

The concept of a short "cycle" fundamentally mischaracterizes how incretin-based therapies work. In the Phase 2 trial, participants on 12 mg once weekly had lost 17.5% at 24 weeks and 24.2% at 48 weeks — the weight loss curve was still descending. Framing retatrutide as something you cycle on and off like a bodybuilding compound ignores the pharmacology and all published evidence. For the actual clinical trial dosing schedules, see Retatrutide Dosage.

Stacking with Supplements

Vinnie recommends stacking retatrutide with two products from "Bolivity Labs": a probiotic called "Biogro" (described as enhancing GLP-1 signaling) and metformin (described as reducing insulin resistance with anti-aging benefits).

ClaimPublished DataVerdict
Probiotics can enhance GLP-1 signaling and make peptide protocols more effectiveSome preclinical research shows certain probiotic strains (e.g., Lactobacillus reuteri) can modestly increase endogenous GLP-1 secretion via short-chain fatty acid production. However, retatrutide is an exogenous receptor agonist — it directly activates GLP-1 receptors, bypassing the body's own GLP-1 production entirely. Adding a probiotic to boost natural GLP-1 while injecting a synthetic GLP-1 agonist is mechanistically redundant.Mechanistically mismatched
Metformin can help reduce insulin resistance and blunt appetite spikesMetformin does reduce hepatic glucose output and improve insulin sensitivity. In the Phase 2 retatrutide diabetes trial, some participants were already on background metformin — but this was not a study designed to test the combination synergistically. Both drugs cause GI side effects (nausea, diarrhea), and combining them may worsen tolerability.Plausible individually, untested as a combination
Metformin may have anti-aging benefitsThe TAME (Targeting Aging with Metformin) trial is ongoing but has not reported results. The anti-aging hypothesis is active research, not established science.Unproven

The supplement recommendations are the most commercially motivated part of the video. Vinnie specifically names branded products from "Bolivity Labs" and asks viewers to email him for a full protocol — a common pattern in peptide influencer content where supplement affiliate sales drive the business model.

The probiotic claim is particularly misleading: boosting the body\u0027s own GLP-1 production is irrelevant when you are already injecting a synthetic GLP-1 receptor agonist at pharmacological doses. It is like taking a vitamin D supplement while lying in direct sunlight.

Claimed Benefits

Vinnie states that retatrutide users are seeing "improved insulin sensitivity, steady fat loss, enhanced energy, and even better blood markers across the board."

ClaimPublished DataVerdict
Improved insulin sensitivityPhase 2 trial: Retatrutide reduced fasting insulin, C-peptide, and HOMA2-IR by up to 50%+ from baseline at 36 weeks. This is supported by published data — at clinical doses (4-12 mg once weekly).Accurate at clinical doses
Steady fat lossPhase 2: Up to 24.2% body weight loss at 48 weeks. Phase 3 TRIUMPH-4: Up to 28.7% (average 71.2 lbs) at 68 weeks. Well-established — at clinical doses over 48-68 weeks.Accurate at clinical doses
Enhanced energyNot measured or reported as an outcome in any published clinical trial. This is anecdotal.No published evidence
Better blood markers across the boardPhase 2 and Phase 3 trials showed favorable shifts in lipids, liver enzymes (ALT, AST), and fasting glucose. A liver disease trial showed 80%+ of participants achieved 70%+ reduction in liver fat.Accurate at clinical doses

The benefits Vinnie lists are real — but they were observed at doses of 4-12 mg once weekly over 36-68 weeks in controlled clinical trials. None of these results have been demonstrated at 1 mg/week split into three micro-doses over 10-12 weeks, which is what his protocol actually delivers. Attributing clinical trial outcomes to an untested protocol is misleading.

For actual results data, see Retatrutide Results.

Frequently Asked Questions

Who is Vinnie from The Peptide Advantage?

Vinnie is the host of The Peptide Advantage, a YouTube channel focused on peptide protocols for fat loss and metabolic health. He is not a physician or medical professional. The channel promotes specific peptide dosing protocols and branded supplements, and collects viewer email addresses via comments for protocol distribution.

Should I dose retatrutide 3 times a week?

No. Every published clinical trial of retatrutide used once-weekly injection. The drug has a half-life of approximately 6 days, which supports weekly dosing. Splitting the dose into 3 sub-injections per week is an untested protocol with no published scientific basis. For the actual dosing schedules used in clinical trials, see Retatrutide Dosage.

Is 333 mcg of retatrutide an effective dose?

There is no published data on 333 mcg as an individual dose. The lowest dose tested in the Phase 2 trial was 1 mg (1,000 mcg) once weekly, which produced the most modest weight loss (8.7% at 48 weeks). The effective doses in Phase 3 trials were 9 mg and 12 mg once weekly. A 333 mcg dose is one-third of the lowest dose ever studied and may be too low to produce meaningful receptor activation.

How long should a retatrutide cycle last?

Retatrutide is not designed for short cycles. Clinical trials ran for 48-68 weeks with continuous treatment. Like other GLP-1 receptor agonists (semaglutide, tirzepatide), weight regain after discontinuation is well-documented. The 10-12 week "beginner cycle" recommended in this video has no basis in published research. For more on treatment duration, see Retatrutide Dosage.

Can you stack retatrutide with metformin?

In the Phase 2 diabetes trial, some participants were on background metformin, and the combination appeared safe. However, there are no published studies designed to test the synergistic combination of retatrutide and metformin for weight loss or anti-aging purposes. Both drugs cause GI side effects, and combining them without medical supervision may worsen tolerability. This should only be done under a doctor\u0027s supervision.

Do probiotics enhance retatrutide\u0027s effectiveness?

Unlikely in a meaningful way. While some probiotics may modestly increase the body\u0027s own GLP-1 production, retatrutide is a synthetic GLP-1 receptor agonist that directly activates the receptor at pharmacological doses. Boosting endogenous GLP-1 secretion when an exogenous agonist is already present would have minimal additive effect. No published studies have tested probiotics in combination with retatrutide.

Sources

  • Vinnie. (2025). "How to Dose Retatrutide GLP3 Beginner\u0027s Guide to Fat Loss & Energy." The Peptide Advantage. Watch on YouTube
  • Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
  • Eli Lilly and Company. (2025). Lilly\u0027s triple agonist retatrutide delivered weight loss of an average of 71.2 pounds in adults with obesity in the TRIUMPH-4 Phase 3 clinical trial. Press release
  • Jastreboff, A.M., et al. (2023). Retatrutide once weekly for treatment of type 2 diabetes. The Lancet. PubMed: 37385280

Medical Disclaimer

The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.

The Peptide Advantage is not a medical channel. The dosing protocol presented in this video is not based on any published clinical trial and directly contradicts the dosing used in every Phase 1, 2, and 3 study of retatrutide. The video also promotes branded supplements and collects personal information (email addresses) from viewers.

Do not use this information to make decisions about your health without consulting a qualified healthcare provider.

This site is not affiliated with The Peptide Advantage, Bolivity Labs, or Eli Lilly and Company.

Sources